Anteris technologies yesterday announced that the first 5 patients have successfully been implanted with Anteris’s DurAVR Valve.
An additional 5 patients are planned for treatment in the first quarter of 2022 to conclude the study.
This is a massive step towards FDA approval as AVR’s technology shows:
- Avoids the need for open heart surgery
- AVR’s heart valve have shown no calcification over 10 years – therefore avoids repeat surgery, and allows younger patients to be treated
- Early signs from first 5 patients have shown DurAVR providing superior haemodynamics
- Commissural alignment, flow characteristics and haemodynamics were proven to be clinically significant
Anteris technologies yesterday announced that the first 5...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.95 |
Change
0.200(1.01%) |
Mkt cap ! $383.4M | |||
| Open | High | Low | Value | Volume |
| $19.95 | $20.00 | $19.83 | $183.2K | 9.187K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25 | $19.75 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.95 | 472 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |